respiratory | pharmaphorum

Thursday 21 May 2026

respiratory

News

vertex

Vertex's latest cystic fibrosis combination approved in US

Vertex’s quest to treat a wider group of patients with cystic fibrosis (CF) continues after the FDA approved its latest combination therapy, Symdeko.

News

Owlstone's ReCIVA is being developed to diagnose lung cancer, but also has applications in precision medicine trials

Owlstone wins funding for IPF lung disease breathalyser test

UK diagnostics company Owlstone Medical was among winners of a $1 million award that will help develop new devices for patients with idiopathic pulmonary fibrosis (IPF).

News

astrazeneca-sign

AZ boosted by COPD triple inhaler results

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.

News

astrazeneca-sign

AZ's cancer and respiratory drugs approved in Japan

Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.

News

gskhouse2

Rumours of $1.65bn GSK bid for respiratory partners Vectura

GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.

Views & Analysis

Lungs-2-16-9

Inhalation technology: the future of effective respiratory t...

Simon Moore discusses non-clinical development channels: technical strategies, formulations and devices.